Capricorn co-leads CHF 23.7m investment in NovaShunt

The series-B financing round was supported by existing investors NeoMed and VI Partners. This marks the first investment from Capricorn Health-tech Fund, which held first close in December 2010.

Capricorn was introduced to the company in early 2009 and found the investment opportunity attractive because it believes the product being developed is unique. Funding will support the company in achieving various approvals and in taking steps towards commercialisation.

As part of the financing round, representatives from the lead investors will join the company's board of directors.

Company
NovaShunt is a medical device company based in Zug, Switzerland. The company is developing technologies that manage fluids within the body in patients suffering from liver cirrhosis, certain cancers and congestive heart failure.

People
Thomas Möller of BioMedInvest, Els Hubloux of Capricorn Venture Partners and Maciek Drozdz of Entrepreneurs Fund will join the company's board of directors.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• Switzerland